


Product Name : TG-1701
Cat. No. : PC-72430
CAS No. : 1858206-58-2
Molecular Formula : C₂₆H₂₃F₂N₅O₃
Molecular Weight : 491.499
Target : BTK
Solubility : 10 mM in DMSO



Biological Activity

TG-1701 (Edralbrutinib, TG1701) is a irreversible, orally available, potent and highly specific **BTK** inhibitor with K_d of 3 nM, IC₅₀ of 6.7 nM, more selective than ibrutinib.

TG-1701 exerts similar activity than the first-in-class BTKi ibrutinib, although with greater selectivity, in in vitro and in vivo models of B-NHL.

TG-1701 impaired BCR downstream signaling in a concentration-dependent manner in IgM-stimulated cells, with maximal effects observed at 100 nM for TG-1701.

TG-1701 shows mean GI₅₀ of 6.4 μM in a set of 10 parental B-NHL cell lines (MCL cell lines GI₅₀=4.3 μM).

TG-1701 blunts Ikaros gene signature, including YES1 and MYC, in early-responder patients as well as in BTKi-sensitive B-NHL cell lines and xenografts.

References

Ribeiro ML, et al. *Clin Cancer Res.* 2021 Dec 1;27(23):6591-6601.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com